Hongri Pharmaceutical pts 12 has been reissued for the second time. The state will give a reply within 100 working days, and an announcement will be issued before the end of March. PTS of Hongri Pharmaceutical Co., Ltd. gives priority to examination and approval, and gives priority to examination and approval after supplementary information.
The new drug PTS of Hongri Pharmaceutical Co., Ltd. obtained two patents in the United States and one patent in China, which was studied by Academician Zhong Nanshan for more than 20 years. Once the annual sales of listed single products reach 65.438+0.5 billion, the PTS production base of Hongri Pharmaceutical has passed the acceptance and will soon be approved for drug registration. The main force has long known that various institutions have opened positions and tried their best to suppress the stock price.